Epidemiological, Clinical, Histopathologic and Therapeutic Characteristics of Marginal Zone Lymphoma: Experience of the Hematology Department of Casablanca in Morocco

Nassima Moufid , Meryem Qachouh, Hajar Maataoui-Belabbes, Amine Benmoussa, Nissrine Khoubila, Mouna Lamchahab, Siham Cherkaoui, Mohamed Rachid, Abdellah Madani

Hematology and Pediatric Oncology Department, Hospital 20 Août 1953, Casablanca, Morocco

soho2023 ELEVENTH ANNUAL MEETING

IBN ROCHD ابن رشد Casablanca الدار البيضاء CHU

FMPC FACULTÉ DE MÉDECINE ET DE PHARMACIE UNIVERSITÉ HASSAN II DE CASABLANCA

INTRODUCTION :

Marginal zone lymphoma (MZL) is a diverse subgroup of B-cell non-Hodgkin lymphomas. This variation contributes to its limited research. It accounts for 7% of all NHL cases, with varying geographic occurrence; our study recorded an incidence of 9%. Optimal treatment for MZL unclear due to limited representation of patients with MZL in phase 3 trials for iNHL.

However, rituximab-based treatments show promising outcomes for MZL.

AIM :

The main objective of our study is to determine our experience of the department of Hematology.

PATIENTS AND METHODS :

The study conduced during the period from February 2018 to December 2022, including all patients followed for marginal zone lymphoma. The data was collected retrospectively using a data sheet from medical records.




RESULTS


PATIENTS CARACTERISTICS :


Patient Number	**59**
Sex ratio	1,2
Avearge age	60 (30-80)
Average consultation time	12 month (1-45)


CLINICAL EXAMINATION	**INCIDENCE**
Performance score < 1	**42%**
Lymphadenopathy	**34%**
Splenomegaly	**25%**


PARACLINICAL EXAMINATION	**INCIDENCE**
Hyperlymphocytosis	**17% (10)**
Hepatitis C	**3% (2)**
LDH > 250 U/L	**28%**
BM Biospsy	**16% Lymphoproliferation**
Digestive endoscopy	**45% ➔ 39% Tumor process**
Bronchoscopy	**5%**














TREATMENT

Localised MALT Gastric 1st linetherapy

	Number of patients	Complete Remission	Partial Remission	Failure
HP treatment	9	5	1	2
R-Chloraminophen	4	4	-	-
R-mini CHOP	1	1	-	-
R-CHOP	2	1	-	-

MALT Parotid 1st line therapy

	Number of patients	CR	PR	RTH	Failure	Relapse
Parotidectomy	1	1	-	-	-	-
R-CVP	3	1	1	1	1-> R-CHOP	-
R-CHOP	1	1	-	-	-	-

Splenic MZL 1st line therapy

	Number of patients	CR	RP	Failure
Splenectomy	6	6	-	-
R-CVP	2	1	1	-

Nodal MZL 1st line therapy

	Number of patients	CR	PR	Failure	Relapse
R-CVP	1	-	1	-	1
R-CHOP	2	-	-	2 (1 died + 1 transferred to another hospital)	

Nodal MZL 2nd line therapy

	Number of patients	CR	PR	Failure
R-Bendamustine	1	-	-	1



CONCLUSION-DISCUSSION :

Our study identifies substantial challenges within a developing country context, encompassing diagnostic delays, heterogeneous populations, diverse treatments, and monitoring lost patients. Tailored strategies are imperative to optimize patient outcomes.

REFERENCES :

Amaador, K, Thieblemont, C, Trotman, J, Minnema, MC. Recent updates in the indolent lymphomas: update on marginal zone lymphoma and Waldenström's macroglobulinemia. *Hematol Oncol*. 2023; 1- 7.

Auñón C, Sanvisens A, Turon E, Vidal-Vila A, Puigdemont M, Osca-Gelis G, Eraso A, Marcos-Gragera R. Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018). Cancer Med. 2023 Jun;12(11):12343-12353. doi: 10.1002/cam4.5935. Epub 2023 Apr 19. PMID: 37076996; PMCID: PMC10278498.